4-Methyl-bicyclo<2.2.2>oct-2-en-1-carbonsaeure | 14233-92-2

• 分子结构分类: 有机化合物 - 有机酸及其衍生物 - 羧酸及其衍生物
• 英文名称: 4-Methyl-bicyclo<2.2.2>oct-2-en-1-carbonsaeure
• 英文别名: 4-Methylbicyclo[2.2.2]oct-2-ene-1-yl carboxylic acid；4-methylbicyclo[2.2.2]oct-2-ene-1-carboxylic acid
• CAS: 14233-92-2
• 化学式: C₁₀H₁₄O₂
• 分子量: 166.22
• InChiKey: AMMPLVWPWSYRDR-UHFFFAOYSA-N

物化性质

• 沸点：
  264.5±9.0 °C(Predicted)
• 密度：
  1.204±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  2.3
• 重原子数：
  12
• 可旋转键数：
  1
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.7
• 拓扑面积：
  37.3
• 氢给体数：
  1
• 氢受体数：
  2

反应信息

• 作为反应物：
  描述：

  4-Methyl-bicyclo<2.2.2>oct-2-en-1-carbonsaeure 生成 4-Methylbicyclo<2.2.2>oct-2-en-1-methylamin
  参考文献：
  名称：

  抗病毒药。I.双环[2.2.2]辛烷和-辛-2-烯胺。

  摘要：

  DOI：

  10.1021/jm00296a021
• 作为产物：
  描述：

  3-Ethoxycarbonyl-6-methyl-2-pyron 、 乙烯 生成 4-Methyl-bicyclo<2.2.2>oct-2-en-1-carbonsaeure
  参考文献：
  名称：

  抗病毒药。I.双环[2.2.2]辛烷和-辛-2-烯胺。

  摘要：

  DOI：

  10.1021/jm00296a021

文献信息

• [EN] INHIBITORS OF BRUTON'S TYROSINE KINASE<br/>[FR] INHIBITEURS DE TYROSINE KINASE DE BRUTON
  申请人：BIOCAD JOINT STOCK CO

  公开号：WO2018092047A1

  公开（公告）日：2018-05-24

  The present invention relates to a new compound of formula I: or pharmaceutically acceptable salt, solvate or stereoisomer thereof, wherein: V1 is C or N, V2 is C(R2) or N, whereby if V1 is C then V2 is N, if V1 is C then V2 is C(R2), or if V1 is N then V2 is C(R2); each n, k is independently 0, 1; each R2, R11 is independently H, D, Hal, CN, NR'R", C(O)NR'R", C1-C6 alkoxy; R3 is H, D, hydroxy, C(O)C1-C6 alkyl, C(O)C2-C6 alkenyl, C(O)C2-C6 alkynyl, C1-C6 alkyl; R4 is H, Hal, CN, CONR'R", hydroxy, C1-C6 alkyl, C1-C6 alkoxy; L is CH2, NH, O or chemical bond; R1 is selected from the group of the fragments, comprising: Fragment 1, Fragment 2, Fragment 3 each A1, A2, A3, A4 is independently CH, N, CHal; each A5, A6, A7, A8, A9 is independently C, CH or N; R5 is H, CN, Hal, CONR'R", C1-C6 alkyl, non-substituted or substituted by one or more halogens; each R' and R" is independently selected from the group, comprising H, C1-C6 alkyl, C1-C6 cycloalkyl, aryl; R6 is selected from the group: [formula II] each R7, R8, R9, R10 is independently vinyl, methylacetylenyl; Hal is CI, Br, I, F, which have properties of inhibitor of Bruton's tyrosine kinase (Btk), to pharmaceutical compositions containing such compounds, and their use as pharmaceuticals for treatment of diseases and disorder.

  本发明涉及一种新的化合物，其化学式为I：或其药学上可接受的盐、溶剂化合物或立体异构体，其中：V1为C或N，V2为C(R2)或N，如果V1为C，则V2为N，如果V1为C，则V2为C(R2)，或者如果V1为N，则V2为C(R2)；每个n，k独立地为0或1；每个R2，R11独立地为H，D，Hal，CN，NR'R"，C(O)NR'R"，C1-C6烷氧基；R3为H，D，羟基，C(O)C1-C6烷基，C(O)C2-C6烯基，C(O)C2-C6炔基，C1-C6烷基；R4为H，Hal，CN，CONR'R"，羟基，C1-C6烷基，C1-C6烷氧基；L为CH2，NH，O或化学键；R1从包括的片段组中选择：片段1，片段2，片段3，每个A1，A2，A3，A4独立地为CH，N，CHal；每个A5，A6，A7，A8，A9独立地为C，CH或N；R5为H，CN，Hal，CONR'R"，C1-C6烷基，未取代或被一个或多个卤素取代；每个R'和R"独立地从包括H，C1-C6烷基，C1-C6环烷基，芳基的组中选择；R6从组中选择：[化学式II]每个R7，R8，R9，R10独立地为乙烯基，甲基乙炔基；Hal为CI，Br，I，F，具有布鲁顿酪氨酸激酶（Btk）抑制剂的性质，以及含有这种化合物的药物组合物，以及它们作为治疗疾病和紊乱的药物的用途。
• [EN] 3-(3,5-DISUBSTITUTED-4-HYDROXYPHENYL)PROPIONAMIDE DERIVATIVES AS CATHEPSIN B INHIBITORS<br/>[FR] DERIVES DE 4-HYDROXYPHENYL-3-3,5-DISUBSTITUE-PROPIONAMIDE EN TANT QU'INHIBITEURS DE CATHEPSINE B
  申请人：AXYS PHARM INC

  公开号：WO2004026851A1

  公开（公告）日：2004-04-01

  The present invention is directed to novel 3-(3,5-disubstituted-4-hydroxyphenyl)-propionamide derivatives that are inhibitors of Cathepsin B. Pharmaceutical composition comprising these compounds, method of treating diseases mediated by Cathepsin B, utilizing these compounds and methods of preparing these compounds are also disclosed.

  本发明涉及一种新型的3-(3,5-二取代-4-羟基苯基)-丙酰胺衍生物，它们是Cathepsin B的抑制剂。还公开了包含这些化合物的药物组合物、治疗由Cathepsin B介导的疾病的方法、利用这些化合物的方法以及制备这些化合物的方法。
• [EN] NOVEL COMPOUNDS AND PHARMACEUTICAL COMPOSITIONS THEREOF FOR THE TREATMENT OF INFLAMMATORY DISORDERS<br/>[FR] NOUVEAUX COMPOSÉS ET COMPOSITIONS PHARMACEUTIQUES LES COMPRENANT POUR LE TRAITEMENT DE TROUBLES INFLAMMATOIRES
  申请人：GALAPAGOS NV

  公开号：WO2017012647A1

  公开（公告）日：2017-01-26

  The present invention discloses compounds according to Formula (I), wherein R1, R3, R4, R5, L1, and Cy are as defined herein. The present invention also provides compounds, methods for the production of said compounds of the invention, pharmaceutical compositions comprising the same and their use in allergic or inflammatory conditions, autoimmune diseases, proliferative diseases, transplantation rejection, diseases involving impairment of cartilage turnover, congenital cartilage malformations, and/or diseases associated with hypersecretion of IL6 and/or interferons. The present invention also methods for the prevention and/or treatment of the aforementioned diseases by administering a compound of the invention.

  本发明公开了根据式（I）的化合物，其中R1、R3、R4、R5、L1和Cy如本文所定义。本发明还提供了该发明的化合物、制备该化合物的方法、包括相同化合物的药物组合物以及它们在过敏或炎症症状、自身免疫疾病、增殖性疾病、移植排斥、涉及软骨周转障碍的疾病、先天软骨畸形和/或与IL6和/或干扰素过度分泌相关的疾病中的使用。本发明还提供了通过给予该发明的化合物来预防和/或治疗上述疾病的方法。
• Novel compounds and compositions as protease inhibitors
  申请人：——

  公开号：US20020052378A1

  公开（公告）日：2002-05-02

  The present invention relates to novel cysteine protease inhibitors of Formula I: 1 the pharmaceutically acceptable salts and N-oxide derivatives thereof, their use as therapeutic agents and methods of making them.

  本发明涉及一种新型半胱氨酸蛋白酶抑制剂的化学式I： 1 其药用盐及N-氧化物衍生物，它们作为治疗剂的用途以及制备它们的方法。
• Ataxia Telengiectasia And RAD3-Related (ATR) Inhibitors And Methods Of Their Use
  申请人：Atrin Pharmaceuticals LLC

  公开号：US20170291911A1

  公开（公告）日：2017-10-12

  The disclosure is directed to compounds and compositions that inhibit Ataxia Telengiectasia And Rad3-Related (ATR) Protein Kinase and methods of their use.

  该披露涉及抑制共济失调毛细血管扩张性和Rad3相关蛋白激酶（ATR）的化合物和组合物，以及它们的使用方法。